Immuneering (IMRX) Interest & Investment Income (2020 - 2026)
Immuneering (IMRX) recorded quarterly Interest & Investment Income of $1.4 million in Q1 2026, down 26.9% quarter-over-quarter from $1.9 million in Q4 2025, and up 210.23% on a YoY basis from $438520.0 in Q1 2025.
Immuneering (IMRX) Interest & Investment Income (2020 - 2026) Analysis & Trends
Immuneering's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 210.23% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $4.0 million (up 77.88% YoY), while the FY2025 annual figure was $3.0 million, up 17.2% from the prior year.
- Interest & Investment Income was $1.4 million for Q1 2026 at Immuneering, down from $1.9 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.9 million in Q4 2025 to a low of $132506.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $683209.8 across 5 years, with a median of $547072.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income jumped 4281.68% in 2022, then plunged 60.78% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $516168.0 in 2022, then surged by 46.1% to $754144.0 in 2023, then slumped by 44.94% to $415240.0 in 2024, then soared by 348.19% to $1.9 million in 2025, then declined by 26.9% to $1.4 million in 2026.
- The last three Interest & Investment Income figures came in at $1.4 million (Q1 2026), $1.9 million (Q4 2025), and $415831.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.36 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 415,831.00 |
| Jun 30, 2025 | 324,013.00 |
| Mar 31, 2025 | 438,520.00 |
| Dec 31, 2024 | 415,240.00 |
| Sep 30, 2024 | 547,072.00 |
| Jun 30, 2024 | 826,104.00 |
| Mar 31, 2024 | 804,884.00 |
| Dec 31, 2023 | 754,144.00 |
| Sep 30, 2023 | 855,532.00 |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 831,274.00 |
| Dec 31, 2022 | 516,168.00 |
| Sep 30, 2022 | 222,985.00 |
| Jun 30, 2022 | 142,799.00 |
| Mar 31, 2022 | 132,506.00 |
| Dec 31, 2021 | 142,885.00 |
| Sep 30, 2021 | 17,400.00 |
| Jun 30, 2021 | 3,259.00 |